Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell
death that activates, rather than suppresses, innate and adaptive immune responses. Such …

Most metastatic cancers remain incurable due to the emergence of apoptosis-resistant
clones, fuelled by intratumour heterogeneity and tumour evolution. To improve treatment …

In recent years, Onco-immunotherapies (OIMTs) have been shown to be a potential therapy
option for cancer. Several immunotherapies have received regulatory approval, while many …

Urologic cancers such as kidney, bladder, prostate, and uroepithelial cancers have recently
become a considerable global health burden, and the response to immunotherapy is limited …

Cancer treatment has seen significant advancements with the introduction of Onco-
immunotherapies (OIMTs). Although some of these therapies have received approval for …

Because therapeutic cancer vaccines can, in theory, eliminate tumor cells specifically with
relatively low toxicity, they have long been considered for application in repressing cancer …

Identification of protein profiling on plasma exosomes by SERS can be a promising strategy
for early cancer diagnosis. However, it is still challenging to detect multiple exosomal …

Diffuse midline gliomas (DMGs) pose treatment challenges due to their location within the
brainstem and invasive nature. Although classical immune checkpoint inhibitors have …

Cancer remains a significant global challenge, with escalating incidence rates and a
substantial burden on healthcare systems worldwide. Herein, we present an in-depth …

Immunotherapy represents the most promising treatment strategy for cancer, but suffers from
compromised therapeutic efficiency due to low immune activity of tumor cells and an …